专利检索 ap:("Novartis Pharmaceuticals Corporation") AND inv:"Yugang Liu" 第 1 页

1.

发明授权
Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations 有权

公开(公告)号：US11642329B2

公开(公告)日：2023-05-09

申请号：US17847588

申请日：2022-06-23

申请人： Novartis Pharmaceuticals Corporation

发明人： Lili Feng , Sven Erik Godtfredsen , Paul Allen Sutton , Mahavir Prashad , Michael J. Girgis , Bin Hu , Yugang Liu , Thomas J. Blacklock , Piotr Henryk Karpinski

IPC分类号： A61K31/216 , A61K31/41 , C07C233/47 , C07D257/04 , A61K45/06 , A61K31/4422 , A61K31/5415 , C07D207/50

CPC分类号： A61K31/216 , A61K31/41 , A61K31/4422 , A61K31/5415 , A61K45/06 , C07C233/47 , C07D207/50 , C07D257/04 , A61K2300/00 , A61K31/216 , A61K2300/00 , A61K31/41 , A61K2300/00

摘要： An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.

2.

发明授权
Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations 有权

公开(公告)号：US11096918B2

公开(公告)日：2021-08-24

申请号：US16579581

申请日：2019-09-23

申请人： Novartis Pharmaceuticals Corporation

发明人： Lili Feng , Sven Erik Godtfredsen , Paul Allen Sutton , Mahavir Prashad , Michael J. Girgis , Bin Hu , Yugang Liu , Thomas J. Blacklock , Piotr Henryk Karpinski

IPC分类号： A61K31/216 , A61K31/41 , C07C233/47 , C07D257/04 , A61K45/06 , A61K31/4422 , A61K31/5415 , C07D207/50

摘要： An amorphous solid form of a compound comprising the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This compound is useful for the treatment of hypertension and/or heart failure.